Navigation Links
Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Date:11/15/2010

ous adverse events were reported.

The poster can be viewed at: http://www.oramed.com/index.php?page=13

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. The Company'orporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking stateme
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
2. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
3. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
4. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
5. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
6. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
7. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
8. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
9. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
10. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
11. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015  Propanc Health Group Corporation (OTCBB: ... on the development of cancer treatments for patients ... product includes PRP, a patented formulation consisting of ... well as the enzyme amylase designed to synergistically ... combination of anti-cancer agents working in combination with ...
(Date:4/23/2015)... FRANCISCO, CA (PRWEB) April 23, 2015 ... delivery, today announced that the United States Patent and ... the Company’s NANOPOR™ technology. US Pat. ... covers Delpor’s microfabricated drug delivery device for ... Delpor’s proprietary NANOPOR™ technology for the sustained (zero-order) release ...
(Date:4/22/2015)... April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today announced ... quarter 2015 on Thursday, May 7, 2015 after the ... webcast and conference call for 4.30 pm ET (1.30 ... Live audio of the conference call will be webcast ... members of the news media and the general public. ...
(Date:4/22/2015)... , April 22, 2015 Steep ... analytics, announced today that it has opened an ... continued growth and expansion.  The common stock investment ... Section 506(c), a law intended to encourage funding ... Prior to 506(c), small businesses largely relied on ...
Breaking Biology Technology:Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... Amex: NBS ) ("NeoStem" or the "Company"), an ... today announced that the Company and its wholly-owned subsidiary, Progenitor ... conferences: the 2011 World Stem Cell Summit, the AABB Annual ... 2011 World Stem Cell Summit – ...
... Oct. 4, 2011 Exosome Diagnostics, a leading ... in personalized medicine, today announced the appointment of ... Donovan, M.D., Ph.D., as chief medical officer, and ...  Raphael Bueno, M.D., associate chief of cardiothoracic surgery ...
... have discovered two early-stage phases of carbon nanotube growth ... tangle of tube growth that ultimately yields to orderly ... in the latest edition of the journal Nanotechnology ... Professor of Physics Zhifeng Ren and researcher Dr. Hengzhi ...
Cached Biology Technology:NeoStem Announces Participation in Multiple October Conferences 2NeoStem Announces Participation in Multiple October Conferences 3NeoStem Announces Participation in Multiple October Conferences 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 2Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 3Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 5Boston College Researchers discover 2 early stages of carbon nanotube growth 2
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Cancer Cell describes a small molecule inhibitor of polo-like kinase1 ... cancer therapy. The compound, ON01910, is a potent inhibitor of ... toxicity. The results of this study have led to clinical ... Plk1 is a molecule that plays a key role in ...
... proteins called phosphatases play a key role in the ... fruit flies and mice by researchers at the University ... collaboration with scientists at the Salk Institute, La Jolla, ... stem cells and for silencing expression of neuronal genes ...
... toward understanding the regulation of blood stem cells and ... research study published in the February issue of Developmental ... to examine the role of a key gene known ... from this research will be useful for future studies ...
Cached Biology News:New drug shows promise as powerful anticancer agent 2New insight into regulation of blood stem cells 2
BD BioCoat Collagen IV 150 mm Culture Dishes...
Polymerase (RNA) II (DNA directed) polypeptide L...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
Biology Products: